Bruker (NASDAQ:BRKR) Announces Quarterly Earnings Results

Bruker (NASDAQ:BRKR) posted its quarterly earnings data on Monday. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12, Zacks reports. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The firm had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the previous year, the firm posted $0.60 EPS. The business’s revenue for the quarter was down .5% compared to the same quarter last year. Bruker updated its FY 2025 guidance to 1.850-1.90 EPS.

Bruker Trading Up 0.5%

BRKR stock traded up $0.22 during trading on Wednesday, hitting $40.60. The company had a trading volume of 1,016,664 shares, compared to its average volume of 2,831,890. The business has a 50-day moving average of $34.65 and a 200-day moving average of $37.01. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. Bruker has a one year low of $28.53 and a one year high of $64.64. The stock has a market cap of $6.16 billion, a PE ratio of 77.96, a PEG ratio of 5.31 and a beta of 1.20.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is 38.46%.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares in the company, valued at $581,016. The trade was a 16.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BRKR. EverSource Wealth Advisors LLC raised its stake in shares of Bruker by 51.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after purchasing an additional 942 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Bruker by 56.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 1,497 shares in the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Bruker during the 2nd quarter valued at about $217,000. Vident Advisory LLC purchased a new position in shares of Bruker during the second quarter worth about $251,000. Finally, Marshall Wace LLP bought a new position in shares of Bruker in the second quarter worth approximately $252,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BRKR has been the subject of several recent research reports. TD Cowen boosted their price target on Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday. UBS Group upped their target price on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research report on Tuesday. Citigroup decreased their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Barclays upped their price objective on shares of Bruker from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Bruker has a consensus rating of “Hold” and a consensus target price of $48.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.